Endometriosis Treatment Market Size, Share & Industry Analysis, By Drug (Orilissa, Myfembree/Ryeqo, and Others), By Drug Class (GnRH Antagonists, GnRH Agonists, and Others), By Route of Administration (Oral and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

ATTRIBUTE 

DETAILS

Study Period

2019-2032

Base Year

2024

Estimated Year 

2025

Forecast Period

2025-2032

Historical Period

2019-2023

Growth Rate

CAGR of 8.41% from 2025-2032

Unit

Value (USD Billion)

Segmentation

By  Drug,  Drug Class,  Route of Administration,  Distribution Channel, and Region

By  Drug

·         Orilissa

·         Myfembree/Ryeqo

·         Others

By  Drug Class

·         GnRH Antagonists

·         GnRH Agonists

·         Others

By  Route of Administration

·         Oral

·         Others

By  Distribution Channel

·         Hospital Pharmacies

·         Retail Pharmacies

·         Online Pharmacies

By Geography

·         North America (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country)

o   U.S.

o   Canada

·         Europe (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)

o   Germany

o   U.K.

o   France

o   Spain

o   Italy

o   Scandinavia

o   Rest of Europe

·         Asia Pacific (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)

o   China

o   Japan

o   India

o   Australia

o   Southeast Asia

o   Rest of Asia Pacific

·         Latin America (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)

o   Brazil

o   Mexico

o   Rest of Latin America

·         Middle East & Africa (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)

o   GCC

o   South Africa

o   Rest of the Middle East & Africa